More MS news articles for Aug 2001

First Published Clinical Study on Eros(TM) Therapy Demonstrates Safety And Effectiveness in Treating Female Sexual Dysfunction

August 3, 2001  2:51pm
Source: PR Newswire

ST. PAUL, Minn., Aug 3, 2001 /PRNewswire via COMTEX/ -- The first published study on the Eros(TM) Therapy in the May Journal of Gender Specific Medicine revealed improvement in sensation, lubrication, ability to achieve orgasm and an increase in sexual satisfaction in women diagnosed with Female Sexual Dysfunction (FSD).

Of the women in the study with complaints of FSD who used the Eros therapy, 80 percent reported increased sensation; 70 percent reported increased lubrication; 60 percent reported an increased ability to achieve orgasm and 90 percent reported increased sexual satisfaction.

Additionally, there were no adverse side effects to using the Eros therapy reported by study participants.

Dr. Steven K. Wilson, clinical professor of urology, University of Arkansas, Van Buren, Ark.; Dr. John R. Delk II, Southwest Impotence Center, Van Buren, Ark.; and Dr. Kevin Billups, clinical assistant professor, University of Minnesota, Minneapolis, conducted the study over a six-week period. The Eros therapy manufacturer UroMetrics, Inc. sponsored the study.

These results reflect similar findings from earlier clinical trials of the Eros therapy that were submitted to the FDA for clearance to market in May 2000.

"We believe this study supports the idea that increasing blood flow to the clitoris can help generate a healthy sexual response," said Dr. Billups. "This was particularly evident when even women without signs of sexual dysfunction experienced improvements in sexual satisfaction after blood flow was increased."

Data from the study also indicated that patients with FSD who were also post-menopausal reported much greater improvement in orgasm response than pre-menopausal women. Sixty-four percent of post-menopausal women reported improved ability to achieve orgasm, compared with 44 percent of pre-menopausal women.

"With so many women affected by FSD, we're pleased that further studies demonstrate the success of the Eros therapy and give physicians a treatment option for their patients," Dr. Billups said.

Additional clinical studies on the effectiveness of the Eros therapy are underway that focus on women with cervical cancer, diabetes, multiple sclerosis and post-menopausal women. These groups of women may be predisposed to experiencing arousal symptoms of FSD resulting from insufficient blood flow to the clitoris and genitalia.

The Eros therapy, the first FDA cleared-to-market treatment for FSD, is a small hand-held patient home device designed to increase blood flow to the clitoris and genitalia. The Eros therapy conditions the sexual responses by applying a gentle vacuum over the clitoris that increases blood flow to the clitoris and genitalia. The expanding arteries put pressure on the nerves that facilitate the natural sexual responses and the benefits of increased clitoral sensation, vaginal lubrication, increase in ability to achieve orgasm and improvement in sexual satisfaction.

The Eros therapy is available by prescription only, and costs $359. Several insurance companies have provided coverage for the device with medical necessity.

The available clinical data is so compelling that until reimbursement policy becomes widespread, UroMetrics is offering patients a manufacturers guarantee 60-day trial period.

FSD is a complex condition that affects more than 43 percent of American women to some degree. Physiological causes of FSD can result from other medical conditions and medications that lead to inadequate blood flow to the clitoris and genitalia resulting in reduced clitoral sensitivity or numbness, a lack of lubrication, difficulty or inability to achieve an orgasm and lowered overall sexual satisfaction. Key risk factors for FSD include trauma to the pelvic area, smoking, vascular disease, high blood pressure, diabetes, menopause or surgery. Medication side effects, including anti-depressants and some blood pressure medications, can reduce sexual desire.

Psychological causes of FSD include low self-esteem or body image or a history of physical or psychological abuse.

For more information on Female Sexual Dysfunction, the Eros therapy and an FSD screening tool, visit HTTP://WWW.WOMENSSEXUALHEALTH.COM

UroMetrics is a privately held medical device company based in St. Paul, Minn. To obtain copies of the clinical studies, or for more information on the Eros therapy or UroMetrics, call 651-774-1552 or visit HTTP://WWW.UROMETRICS.COM

SOURCE UroMetrics, Inc.

CONTACT:    Kim Wickline, +1-952-897-9461, , or Saunya
                  Peterson, +1-952-897-9469, , both of Kerker for
                  UroMetrics, Inc.

Copyright (C) 2001 PR Newswire